Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 4/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17241252 | 0.80 | ALDH1A1 (0.39) | DAOALDH1A1 | |
| SCHEMBL17241205 | 0.80 | ALDH1A1 (0.43) | DAOALDH1A1 | |
| SCHEMBL2052369 | 0.79 | DAO (0.40) | DAOMAPTIDO1GPR84 | |
| SCHEMBL461886 | 0.75 | — | — | |
| SCHEMBL16561361 | 0.75 | IDO1 (0.58) | DAOALDH1A1IDO1LOXL2TAAR1 | |
| SCHEMBL1468357 | 0.75 | IDO1 (0.58) | DAOALDH1A1IDO1LOXL2TAAR1 | |
| SCHEMBL11534091 | 0.75 | MAPT (0.36) | DAOALDH1A1MAPT | |
| SCHEMBL16020926 | 0.73 | MAPT (0.42) | DAOALDH1A1MAPTIDO1LOXL2 | |
| SCHEMBL15579011 | 0.73 | DAO (0.77) | DAO | |
| SCHEMBL11161344 | 0.72 | ERCC1 (0.53) | EPHX2ALDH1A1MAPTSCN8ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | VIIV HEALTHCARE CO (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | VIIV HEALTHCARE CO (US) | 2015-08-13 | — | — | US | disclosed |
| US-20140256713-A1 | 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| US-20140256713-A1 | 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| US-8691991-B2 | 2-oxonaphthyridine-3-carboxamides HIV integrase inhibitors | SHIONOGI & CO., LTD. (JP) | 2014-04-08 | — | — | US | disclosed |
| US-8691991-B2 | 2-oxonaphthyridine-3-carboxamides HIV integrase inhibitors | SHIONOGI & CO., LTD. (JP) | 2014-04-08 | — | — | US | disclosed |
| EP-1720856-B1 | HIV INTEGRASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-08-14 | — | — | EP | disclosed |
| EP-1720856-B1 | HIV INTEGRASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20080214503-A1 | Hiv Integrase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| US-20080214503-A1 | Hiv Integrase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| EP-1910356-A2 | HIV INTEGRASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20070124152-A1 | Hiv Integrase Inhibitors | GLAXOSMITHKLINE LLC | 2007-05-31 | — | — | US | disclosed |
| US-20070124152-A1 | Hiv Integrase Inhibitors | GLAXOSMITHKLINE LLC | 2007-05-31 | — | — | US | disclosed |
| US-20070124152-A1 | Hiv Integrase Inhibitors | GLAXOSMITHKLINE LLC | 2007-05-31 | — | — | US | disclosed |
| WO-2007019101-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019101-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019100-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019100-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| EP-1720856-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005077050-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256713-A1 | 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS | BCDIN3D, DUT, SAMHD1 | DAO 1228/4885EPHX2 4649/4885ALDH1A1 3812/4885 |
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | ING2, API5, SAMHD1 | DAO 1741/4885EPHX2 4471/4885ALDH1A1 3073/4885 |
| US-20080214503-A1 | Hiv Integrase Inhibitors | SAMHD1, ACIN1, API5 | DAO 1433/4885EPHX2 4567/4885ALDH1A1 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.